Opinion|Videos|June 1, 2026
Indirect Trial Comparisons in Metastatic Castration-Sensitive Prostate Cancer
Fact checked by: Tracy Ann Politowicz
This episode examines how indirect trial comparisons can help guide ARPI selection in metastatic castration-sensitive prostate cancer when head-to-head studies are unavailable, while emphasizing the importance of patient-specific factors, tolerability, and clinical judgment.
Episodes in this series
This episode examines how indirect trial comparisons can help guide the selection of an androgen receptor pathway inhibitor (ARPI) in metastatic castration-sensitive prostate cancer when head-to-head studies are unavailable, while emphasizing the importance of patient-specific factors, tolerability, and clinical judgment.
Related Content
Latest CME
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
3
Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer
4
EV plus pembro approval reframes first conversation in MIBC diagnosis
5